Table 4.
Bleeding manifestations in inhibitor-positive and negative patients.
| Clinical symptoms | Total PWHA
(n=300) |
Severe PWHA
(n=219) |
||||
|---|---|---|---|---|---|---|
| Inhibitor positive (n = 29) |
Inhibitor negative (n = 271) |
p-value | Inhibitor positive (n = 29) |
Inhibitor negative (n = 190) |
p-value | |
| Hemarthrosis | ||||||
| Present | 27 (93.1%) | 242 (89.3%) | 0.52b | 27 (93.1%) | 172 (89.47%) | 0.918b |
| Absent | 2 (6.9%) | 29 (10.7%) | 2 (6.9%) | 18(10.53%) | ||
| Gum bleed | ||||||
| Present | 17 (58.6%) | 113 (41.7%) | 0.08b | 17 (58.6%) | 69 (36.3%) | 0.369b |
| Absent | 12 (41.4%) | 158 (58.3%) | 12 (41.4%) | 121 (63.7%) | ||
| CNS bleed | ||||||
| Present | 6 (20.7%) | 8 (3.0%) | 0.0001*b | 6 (20.7%) | 8 (4.2%) | 0.003*b |
| Absent | 23 (79.3%) | 263 (97.0%) | 23 (79.3%) | 182 (95.8%) | ||
| Epistaxis | ||||||
| Present | 10 (34.5%) | 64 (23.6%) | 0.19b | 10 (34.5%) | 43 (22.6%) | 0.248b |
| Absent | 19 (65.5%) | 207 (76.4%) | 19 (65.5%) | 147 (77.4%) | ||
| GI bleed | ||||||
| Present | 6 (20.7%) | 44 (16.2%) | 0.54b | 6 (20.7%) | 38 (20%) | 0.931b |
| Absent | 23 (79.3%) | 227 (83.8%) | 23 (79.3%) | 152 (80%) | ||
| Hematuria | ||||||
| Present | 14 (48.3%) | 55 (20.3%) | 0.001*b | 14 (48.3%) | 38 (20%) | 0.001*b |
| Absent | 15 (51.7%) | 216 (79.7%) | 15 (51.7%) | 152 (80%) | ||
| Melena | ||||||
| Present | 9 (31.0%) | 56 (20.7%) | 0.20b | 9 (31.0%) | 39 (20.5%) | 0.301b |
| Absent | 20 (69.0%) | 214 (79.3%) | 20 (69.0%) | 151 (79.5%) | ||
| Ecchymoses | ||||||
| Present | 15 (51.7%) | 156 (57.6%) | 0.54b | 15 (51.7%) | 107 (56.3%) | 0.792b |
| Absent | 14 (48.3%) | 115 (42.4%) | 14 (48.3%) | 83 (43.7%) | ||
b
Chi-square//Fisher’s exact test; *significant (p-value <0.05).
CNS, central nervous system; GI, gastrointestinal; PWHA, patients with hemophilia A.